With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform and a growing portfolio of therapeutic candidates across all stages of development, we are advancing toward our goal of delivering effective medicines to transform the lives of people living with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. Establish, operate, and continuously improve internal analytical laboratory capabilities, including instrumentation, workflows, documentation, data integrity, safety, and laboratory readiness; identify and implement innovative technologies and practical improvements that strengthen laboratory and program performance.